T1	Participants 827 851	263 randomized patients,
T2	Participants 852 864	256 patients
T3	Participants 1782 1789	groups.
T4	Participants 1286 1291	group
T5	Participants 1000 1026	fimasartan treatment group
T6	Participants 916 947	fimasartan/HCTZ treatment group
T7	Participants 1199 1230	fimasartan/HCTZ treatment group
T8	Participants 1265 1288	fimasartan treatment gr
T9	Participants 1432 1440	patients
T10	Participants 1572 1603	fimasartan/HCTZ treatment group
T11	Participants 1616 1642	fimasartan treatment group
